Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2023)

Candel Therapeutics' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $300000.0 for Q4 2023.

  • For Q4 2023, Depreciation & Amortization (CF) rose 35.75% year-over-year to $300000.0; the TTM value through Dec 2023 reached $966000.0, up 24.97%, while the annual FY2024 figure was $990000.0, 1.0% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2023 was $300000.0 at Candel Therapeutics, up from $200000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $300000.0 in Q4 2023 and bottomed at $6000.0 in Q4 2020.
  • The 4-year median for Depreciation & Amortization (CF) is $182500.0 (2021), against an average of $144428.6.
  • The largest YoY upside for Depreciation & Amortization (CF) was 2866.67% in 2021 against a maximum downside of 53.33% in 2021.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $6000.0 in 2020, then surged by 2866.67% to $178000.0 in 2021, then rose by 24.16% to $221000.0 in 2022, then surged by 35.75% to $300000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Depreciation & Amortization (CF) are $300000.0 (Q4 2023), $200000.0 (Q3 2023), and $236000.0 (Q2 2023).